• PALOMA Soars!

    by Arnold DuBell  |  Jun 7, 2016
    Oncology Conference Insight: ASCO 2016 --- The CDK 4/6 inhibitor Ibrance® (palbociclib, Pfizer) burst onto the scene in February 2015 with its original approval from the U.S. Food and Drug Administration (FDA) for treatment of newly diagnosed HR+/HER2- breast cancer.
  • PD-1 Inhibitors Running Neck-and-Neck in Head and Neck

    by Stephanie Hawthorne  |  Jun 6, 2016
    Oncology Conference Insight: ASCO 2016 --- Patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who are refractory to platinum-based therapy have a poor prognosis with a median overall survival of six months or less.
  • Oncology Conference Insight: ASCO 2016 --- The pace of treatment in metastatic melanoma has significantly accelerated in the past couple of years. What was once a disease beset by toxic and largely ineffective treatments now enjoys a number of effective agents that have reduced the mortality of this aggressive disease.
  • CASTOR Shines in Relapsed/Refractory Multiple Myeloma

    by Jay Grisolano  |  Jun 5, 2016
    Oncology Conference Insight: ASCO 2016 --- The armamentarium of treatment options available for patients with multiple myeloma continues to grow as the result of several recent, successful novel therapeutic agents in development.
  • VYXEOS scores a 10 over 7+3

    by Stephanie Hawthorne  |  Jun 4, 2016
    Oncology Conference Insight: ASCO 2016 --- Therapeutic approaches for acute myeloid leukemia (AML) have gone unchanged for several years. Most newly diagnosed patients achieve complete remission (CR) with a combination regimen of cytarabine plus an anthracycline (7+3 most commonly). However, the high rate of CR comes at the cost of a high level of toxicities with this regimen.